Cargando…

Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy

The study of myelodysplastic syndromes (MDS) in murine models has now indicated the possible involvement of the bone marrow microenvironment in the generation of dysplastic hematopoietic cells. However, there is scant work on patient samples and the role of hypomethylating agents on the bone marrow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poon, Zhiyong, Dighe, Niraja, Venkatesan, Subhashree S., Cheung, Alice M. S., Fan, Xiubo, Bari, Sudipto, Hota, Monalisa, Ghosh, Sujoy, Hwang, William Y. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756222/ https://www.ncbi.nlm.nih.gov/pubmed/30575819 http://dx.doi.org/10.1038/s41375-018-0310-y

Ejemplares similares

Correction: Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy
por: Poon, Zhiyong, et al.
Publicado: (2019)

Ex Vivo Expansion of CD34(+)CD90(+)CD49f(+) Hematopoietic Stem and Progenitor Cells from Non‐Enriched Umbilical Cord Blood with Azole Compounds
por: Bari, Sudipto, et al.
Publicado: (2018)

Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs
por: Li, Hongjiao, et al.
Publicado: (2023)

Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts
por: Yahng, Seung-Ah, et al.
Publicado: (2016)

What Clonal Hematopoiesis Can Teach Us About MDS
por: Chan, Irenaeus C. C., et al.
Publicado: (2022)

Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS
por: Buck, Michèle C., et al.
Publicado: (2023)

Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis
por: Ji, Jiang, et al.
Publicado: (2020)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
por: Trowbridge, Jennifer J., et al.
Publicado: (2021)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
por: Jilg, Stefanie, et al.
Publicado: (2019)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Bone Marrow Fat and Hematopoiesis
por: Wang, Huifang, et al.
Publicado: (2018)

Traditional Chinese Medicine Containing Arsenic Treated MDS Patients Effectively through Regulating Aberrant Hypomethylation
por: Zhou, Qing-bing, et al.
Publicado: (2020)

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents
por: Duchmann, M, et al.
Publicado: (2017)

Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment
por: Asada, Noboru
Publicado: (2018)

Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis
por: Wang, Xiaofang, et al.
Publicado: (2014)

Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis
por: Wang, Xiaofang, et al.
Publicado: (2021)

Interactions between MSCs and Immune Cells: Implications for Bone Healing
por: Kovach, Tracy K., et al.
Publicado: (2015)

Radiation induces iatrogenic immunosuppression by indirectly affecting hematopoiesis in bone marrow
por: Kapoor, Vaishali, et al.
Publicado: (2020)

Bone Marrow Defects and Platelet Function: A Focus on MDS and CLL
por: Luu, Sarah, et al.
Publicado: (2018)

Extramedullary Hematopoiesis in Lymphangioma - A Cytological Study
por: Kushwaha, Pritika, et al.
Publicado: (2021)

Anatomy of Hematopoiesis and Local Microenvironments in the Bone Marrow. Where to?
por: Wu, Qingqing, et al.
Publicado: (2021)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
por: Ørskov, Andreas D., et al.
Publicado: (2015)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858
por: Eksioglu, Erika A., et al.
Publicado: (2017)

The impact of chronic intermittent hypoxia on hematopoiesis and the bone marrow microenvironment
por: Alvarez-Martins, Inês, et al.
Publicado: (2016)

Myelodysplastic hematopoiesis mimicking the bone marrow in a mediastinal myelolipoma
por: Takano, Hina, et al.
Publicado: (2017)

Distinct bone marrow blood vessels differentially regulate hematopoiesis
por: Itkin, Tomer, et al.
Publicado: (2016)

Dysregulated hematopoiesis in bone marrow marks severe COVID-19
por: Wang, Xin, et al.
Publicado: (2021)

How Does Lifestyle Affect Hematopoiesis and the Bone Marrow Microenvironment?
por: Vanhie, James J., et al.
Publicado: (2022)

P706: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISKMYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINEDEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME
por: Dimitriou, Despoina, et al.
Publicado: (2023)

Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor–TRAF6 signaling
por: Varney, Melinda E., et al.
Publicado: (2015)

Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment
por: Kovtonyuk, Larisa V., et al.
Publicado: (2016)

The Differentiation Balance of Bone Marrow Mesenchymal Stem Cells Is Crucial to Hematopoiesis
por: Wu, Jiang, et al.
Publicado: (2018)

Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party
por: Kim, Da Jung, et al.
Publicado: (2017)

PB1989: STUDY ON THE RELATIONSHIP BETWEEN MDS AND ABNORMAL LIPID METABOLISM IN BONE MARROW MICROENVIRONMENT
por: LI, Yuchun, et al.
Publicado: (2023)

Human fetal liver MSCs are more effective than adult bone marrow MSCs for their immunosuppressive, immunomodulatory, and Foxp3(+) T reg induction capacity
por: Yu, Yi, et al.
Publicado: (2021)

Deficiency in the omega-3 lysolipid transporter Mfsd2a leads to aberrant oligodendrocyte lineage development and hypomyelination
por: Sengottuvel, Vetrivel, et al.
Publicado: (2023)

Protocol for performing consecutive bone marrow transplants in mice to study the role of marrow niche in supporting hematopoiesis
por: Gopal, Aparna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4pkcccfg2cnlknhqk8d2rb2i16